What is the best medicine for strengthening bones?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Best Medicines for Strengthening Bones

Oral bisphosphonates are the first-line pharmacological treatment for strengthening bones due to their proven efficacy, safety profile, and cost-effectiveness compared to other osteoporosis medications. 1

Assessment of Bone Health and Fracture Risk

Before initiating treatment, bone health should be evaluated through:

  • Bone mineral density (BMD) testing via DEXA scan
  • FRAX calculator to assess overall fracture risk
  • Assessment of modifiable risk factors
  • Calcium and vitamin D status

Treatment Algorithm Based on Fracture Risk

For Adults ≥40 Years:

  1. Low Fracture Risk (T-score >-2.5 and FRAX 10-year risk <20% for major osteoporotic fracture and <3% for hip fracture):

    • Optimize calcium intake (1,000-1,200 mg/day) and vitamin D (600-800 IU/day)
    • Lifestyle modifications (weight-bearing exercise, smoking cessation, limiting alcohol)
    • No pharmacological therapy needed 2
  2. Moderate Fracture Risk (T-score ≤-2.5 but >-3.5 OR FRAX 10-year risk ≥20% but <30% for major osteoporotic fracture or ≥3% but <4.5% for hip fracture):

    • Oral bisphosphonates (first choice)
    • Alternatives if oral bisphosphonates not appropriate (in order of preference): a) IV bisphosphonates b) Teriparatide c) Denosumab d) Raloxifene (for postmenopausal women only) 2, 1
  3. High Fracture Risk (Prior osteoporotic fracture OR T-score ≤-3.5 OR FRAX 10-year risk ≥30% for major osteoporotic fracture or ≥4.5% for hip fracture):

    • Oral bisphosphonates (first choice)
    • Same alternative options as for moderate risk, with stronger recommendation for treatment 2

For Adults <40 Years:

  • Low fracture risk: Calcium, vitamin D, and lifestyle modifications
  • Moderate-to-high risk: Similar approach as for older adults, starting with oral bisphosphonates 2

Specific Medication Options

First-Line Therapy:

  • Oral Bisphosphonates:
    • Alendronate: 70 mg orally once weekly
    • Risedronate: 35 mg orally once weekly or 150 mg monthly 1

Second-Line Options:

  • IV Bisphosphonates:

    • Zoledronic acid: 5 mg intravenously once yearly 1
  • Anabolic Agents:

    • Teriparatide: Stimulates new bone formation by binding to specific cell-surface receptors, increasing skeletal mass and bone strength 3
  • RANK-L Inhibitors:

    • Denosumab: 60 mg subcutaneously every 6 months; blocks osteoclast differentiation and function 4

Essential Supplements

  • Calcium: 1,000-1,200 mg daily (preferably from dietary sources)
  • Vitamin D: 600-800 IU daily (serum level ≥20 ng/ml) 2, 1

Calcium citrate may be better absorbed than calcium carbonate, especially in older adults or those taking acid-reducing medications 5.

Lifestyle Modifications

  • Regular weight-bearing and resistance training exercise (at least 30 minutes daily)
  • Maintaining weight in recommended range
  • Smoking cessation
  • Limiting alcohol intake to 1-2 drinks per day
  • Fall prevention strategies 2, 1

Important Considerations and Caveats

  1. Medication Selection Factors:

    • Oral bisphosphonates require proper administration (taken on empty stomach with water, remaining upright for 30-60 minutes)
    • Patients with esophageal problems should consider alternatives to oral bisphosphonates
    • Renal function must be considered when prescribing bisphosphonates
  2. Monitoring:

    • BMD testing every 1-2 years during treatment
    • After 5 years of bisphosphonate therapy, reevaluate fracture risk to determine whether to continue or discontinue treatment 1
  3. Safety Concerns:

    • Bisphosphonates: Rare risk of osteonecrosis of the jaw and atypical femur fractures
    • Denosumab: Risk of hypocalcemia; rebound bone loss if discontinued 4
    • Teriparatide: Limited to 2 years of treatment due to safety concerns 3
    • Calcium supplements: Potential increased risk of kidney stones and cardiovascular events 6, 7
  4. Special Populations:

    • Cancer patients on treatments that affect bone health require special consideration
    • Patients on glucocorticoids should receive preventive therapy at lower thresholds 2

The evidence strongly supports that for most patients requiring pharmacological intervention for bone strengthening, oral bisphosphonates provide the best balance of efficacy, safety, and cost-effectiveness 2, 1.

References

Guideline

Osteoporosis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.